Limits...
I(f) current channel inhibitor (ivabradine) deserves cardioprotective effect via down-regulating the expression of matrix metalloproteinase (MMP)-2 and attenuating apoptosis in diabetic mice.

Chen SL, Hu ZY, Zuo GF, Li MH, Li B - BMC Cardiovasc Disord (2014)

Bottom Line: Our results showed that ivabradine treatment attenuated the expression and staining score of matrix metalloproteinase (MMP)-2, induced the dephosphorylation of caspase 3, BAX and MMP-2, and enhanced the phosphorylation of NF-κB.Ivabradine treatment led to a significant improvement in cardiac function.Ivabradine significantly improved cardiac function by attenuating apoptosis and inhibiting the expression and activity of MMP-2 in diabetic mice, which underscored the novel clinical implications of ivabradine for diabetic patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing 210006, China. chmengx@126.com.

ABSTRACT

Background: Ivabradine (IVBD), a novel I(f)-channel inhibitor and specific heart rate-lowering agent, is known to have anti-oxidative activity that promotes endothelial function. However, the molecular mechanism through which IVBD acts on cardiac function has yet to be elucidated, especially in experimental diabetic animals.

Methods: For this reason, twenty diabetic mice were randomly assigned to IVBD-treated (10 mg/kg/day) and control (saline) groups. After a 3-month treatment, microarray assay was performed to identify differentia expressed genes, and cardiac function was measured by echocardiography, with subsequent immunohistochemistry analysis and western blotting.

Results: Our results showed that ivabradine treatment attenuated the expression and staining score of matrix metalloproteinase (MMP)-2, induced the dephosphorylation of caspase 3, BAX and MMP-2, and enhanced the phosphorylation of NF-κB. Ivabradine treatment led to a significant improvement in cardiac function.

Conclusion: Ivabradine significantly improved cardiac function by attenuating apoptosis and inhibiting the expression and activity of MMP-2 in diabetic mice, which underscored the novel clinical implications of ivabradine for diabetic patients.

Show MeSH
Comparison of MMP-2 staining before (A) and 3 months after (B) ivabradine treatment. The difference in staining score reached significance (p = 0.048) (C).
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4230832&req=5

Fig3: Comparison of MMP-2 staining before (A) and 3 months after (B) ivabradine treatment. The difference in staining score reached significance (p = 0.048) (C).

Mentions: Based on the microarray analysis, the up-regulation of MMP-2 expression was analyzed by immunostaining, and the results are shown in Table 4 and Figure 3. The mean staining score and staining intensity in the ivabradine group were significantly improved (2.1 ± 0.2 scores and 1.9 ± 0.3 grade), compared with the control group (3.6 ± 0.3 scores, p = 0.038 and 3.9 ± 0.3 grade, p = 0.022, respectively).Table 4


I(f) current channel inhibitor (ivabradine) deserves cardioprotective effect via down-regulating the expression of matrix metalloproteinase (MMP)-2 and attenuating apoptosis in diabetic mice.

Chen SL, Hu ZY, Zuo GF, Li MH, Li B - BMC Cardiovasc Disord (2014)

Comparison of MMP-2 staining before (A) and 3 months after (B) ivabradine treatment. The difference in staining score reached significance (p = 0.048) (C).
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4230832&req=5

Fig3: Comparison of MMP-2 staining before (A) and 3 months after (B) ivabradine treatment. The difference in staining score reached significance (p = 0.048) (C).
Mentions: Based on the microarray analysis, the up-regulation of MMP-2 expression was analyzed by immunostaining, and the results are shown in Table 4 and Figure 3. The mean staining score and staining intensity in the ivabradine group were significantly improved (2.1 ± 0.2 scores and 1.9 ± 0.3 grade), compared with the control group (3.6 ± 0.3 scores, p = 0.038 and 3.9 ± 0.3 grade, p = 0.022, respectively).Table 4

Bottom Line: Our results showed that ivabradine treatment attenuated the expression and staining score of matrix metalloproteinase (MMP)-2, induced the dephosphorylation of caspase 3, BAX and MMP-2, and enhanced the phosphorylation of NF-κB.Ivabradine treatment led to a significant improvement in cardiac function.Ivabradine significantly improved cardiac function by attenuating apoptosis and inhibiting the expression and activity of MMP-2 in diabetic mice, which underscored the novel clinical implications of ivabradine for diabetic patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing 210006, China. chmengx@126.com.

ABSTRACT

Background: Ivabradine (IVBD), a novel I(f)-channel inhibitor and specific heart rate-lowering agent, is known to have anti-oxidative activity that promotes endothelial function. However, the molecular mechanism through which IVBD acts on cardiac function has yet to be elucidated, especially in experimental diabetic animals.

Methods: For this reason, twenty diabetic mice were randomly assigned to IVBD-treated (10 mg/kg/day) and control (saline) groups. After a 3-month treatment, microarray assay was performed to identify differentia expressed genes, and cardiac function was measured by echocardiography, with subsequent immunohistochemistry analysis and western blotting.

Results: Our results showed that ivabradine treatment attenuated the expression and staining score of matrix metalloproteinase (MMP)-2, induced the dephosphorylation of caspase 3, BAX and MMP-2, and enhanced the phosphorylation of NF-κB. Ivabradine treatment led to a significant improvement in cardiac function.

Conclusion: Ivabradine significantly improved cardiac function by attenuating apoptosis and inhibiting the expression and activity of MMP-2 in diabetic mice, which underscored the novel clinical implications of ivabradine for diabetic patients.

Show MeSH